Literature DB >> 27157527

Efficacy and mucosal toxicity of concomitant chemo-radiotherapy in patients with locally-advanced squamous cell carcinoma of the head-and-neck in the light of a novel mathematical model.

Lidia Strigari1, Paola Pinnarò2, Paolo Carlini3, Francesco Torino4, Silvia Strolin5, Silvia Minosse5, Giuseppe Sanguineti2, Marcello Benassi6.   

Abstract

BACKGROUND: In the last several decades, combined radiotherapy (RT) and chemotherapy (CT) have been recognized as feasible in locally-advanced-squamous-cell-carcinoma of the head-and-neck (LA-HNSCC). Several meta-analyses identified concurrent RT+CT (CRT) most likely effective approach respect to RT-alone. However, radiobiological models comparing different chemotherapeutic schedules against delivered RT fractionation schedule for overall survival and toxicity are still needed. METHODS AND MATERIALS: Based on 9 randomized trials (2785 patients), radiobiological models and multivariate logistic regression model were used to derive dose-response curves and estimate the 5-year-overall survival (OS) and ≥G3 acute mucositis rate of CRT or RT-alone.
RESULTS: Equivalent dose at 2 Gy/fraction (EQD2) was calculated using the linear quadratic model. The effect of CRT schedules, considering the CT type and its administration schedule and the HPV status of tumors were estimated using the univariate/multivariate logistic regression. The multivariate logistic regression model for 5y-OS indicated EQD2 and the type of CT, the chemo-sensitization fraction and the HPV status significant prognostic factors, while for toxicity both EQD2 and the concomitant administration of 5-fluorouracil (5Fu) resulted as significant prognostic factors. Combined schedules cisplatin (DDP)+/-5Fu+RT produced the higher OS compared with combined carboplatin+/-5Fu+RT or RT-alone. The concomitant administration of Fu and schedule with high EQD2 increase the rate of observed ≥G3 acute mucositis.
CONCLUSION: Multivariate logistic regression models can be used to predict CRT effect in terms of OS and ≥G3-mucositis, contributing to the identification of novel treatment schedules.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Advanced; Efficacy; Head and neck; Radiobiology; Toxicity; Tumors

Mesh:

Year:  2016        PMID: 27157527     DOI: 10.1016/j.critrevonc.2016.04.004

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  6 in total

1.  UPFRONT DPD DEFICIENCY DETECTION TO SECURE 5-FU ADMINISTRATION: PART 2- APPLICATION TO HEAD-AND-NECK CANCER PATIENTS.

Authors:  Manon Launay; Joseph Ciccolini; Claire Fournel; Carmelo Blanquicett; Charlotte Dupuis; Nicolas Fakhry; Florence Duffaud; Sébastien Salas; Bruno Lacarelle
Journal:  Clin Cancer Drugs       Date:  2017

2.  A meta-analysis of the abscopal effect in preclinical models: Is the biologically effective dose a relevant physical trigger?

Authors:  Raffaella Marconi; Silvia Strolin; Gianluca Bossi; Lidia Strigari
Journal:  PLoS One       Date:  2017-02-21       Impact factor: 3.240

Review 3.  Assessing Novel Drugs and Radiation Technology in the Chemoradiation of Oropharyngeal Cancer.

Authors:  Agostino Cristaudo; Mitchell Hickman; Charles Fong; Paul Sanghera; Andrew Hartley
Journal:  Medicines (Basel)       Date:  2018-06-27

4.  The prognostic value of hypoxia-inducible factor-1α in advanced cancer survivors: a meta-analysis with trial sequential analysis.

Authors:  Susu Han; Tao Huang; Fenggang Hou; Liting Yao; Xiyu Wang; Xing Wu
Journal:  Ther Adv Med Oncol       Date:  2019-09-24       Impact factor: 8.168

5.  Associations of GWAS-Identified Risk Loci with Progression, Efficacy and Toxicity of Radiotherapy of Head and Neck Squamous Cell Carcinoma Treated with Radiotherapy.

Authors:  Qinghuan Li; Yi Liang; Zeng Liu; Chuanyun Yu
Journal:  Pharmgenomics Pers Med       Date:  2021-09-21

6.  Local Irradiation Modulates the Pharmacokinetics of Metabolites in 5-Fluorouracil-Radiotherapy-Pharmacokinetics Phenomenon.

Authors:  Ju-Han Liu; Tung-Hu Tsai; Yu-Jen Chen; Li-Ying Wang; Hsin-Yu Liu; Chen-Hsi Hsieh
Journal:  Front Pharmacol       Date:  2020-02-27       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.